Status:
TERMINATED
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
Detailed Description
The study was terminated on Oct. 18, 2007. This study is not a post approval commitment study. Pfizer decided to cancel new trials because of the decision to withdraw Exubera® (inhaled insulin) due to...
Eligibility Criteria
Inclusion
- Subjects with Type 1 or Type 2 Diabetes Mellitus who participated in previous Phase 2 extension protocols
Exclusion
- Smoking
- Pregnancy
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT00143247
Start Date
March 1 2003
End Date
January 1 2008
Last Update
April 15 2010
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
San Diego, California, United States, 92123
2
Pfizer Investigational Site
New Haven, Connecticut, United States, 06504
3
Pfizer Investigational Site
Miami, Florida, United States, 33136
4
Pfizer Investigational Site
Chicago, Illinois, United States, 60610